Pfizer and BioNTech requested Food and Drug Administration emergency authorization of their COVID-19 vaccine for children ages 5 to 11, the companies announced Thursday.Pfizer took to Twitter to share the news, writing: “With new cases in children in the U.S. continuing to be at a high level, this submission is an important step in our ongoing effort against #COVID19.”CLICK HERE FOR FULL CORONAVIRUS COVERAGEThe news comes just over a week after Pfizer-BioNTech submitted clinical trial data from a COVID-19 vaccine study among kids ages 5-11 to the FDA. Trial data included recent findings among 2,268 participants ages 5-11, which suggested a smaller dose shot was safe, well tolerated and resulted in neutralizing antibody responses.The companies previously announced that trial results on younger age groups, like children ages 6 months to under 5 years, are expected by the fourth quarter.This is a developing story, please check back for updates.
Source link

सिगवर्क इंडिया में अपने जीआईसीसी को मजबूत करने के लिए 350 करोड़ रुपये के निवेश के साथ अनुसंधान और विकास, उत्पादन और स्थायी नवाचार को गति देने के लिए।
दिल्ली: प्रिंटिंग इंक्स और कोटिंग्स के लिए पैकेजिंग के लिए वैश्विक नेता सिगवर्क ने भारत में अपनी संचालन…